See more : E&P Global Holdings Limited (1142.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Personalis, Inc. (PSNL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Personalis, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Advanced International Multitech Co., Ltd. (8938.TWO) Income Statement Analysis – Financial Results
- Moong Pattana International Public Company Limited (MOONG.BK) Income Statement Analysis – Financial Results
- GAIL (India) Limited (GAILF) Income Statement Analysis – Financial Results
- Ramsay Générale de Santé SA (GDS.PA) Income Statement Analysis – Financial Results
- Glen Burnie Bancorp (GLBZ) Income Statement Analysis – Financial Results
Personalis, Inc. (PSNL)
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 73.48M | 65.05M | 85.49M | 78.65M | 65.21M | 37.77M | 9.39M |
| Cost of Revenue | 55.27M | 51.70M | 53.84M | 58.53M | 43.13M | 25.97M | 11.74M |
| Gross Profit | 18.21M | 13.35M | 31.66M | 20.11M | 22.08M | 11.81M | -2.34M |
| Gross Profit Ratio | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Research & Development | 64.78M | 64.91M | 49.31M | 28.57M | 22.42M | 14.30M | 9.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.27M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.73M | 63.97M | 47.70M | 33.69M | 22.08M | 11.27M | 9.90M |
| Other Expenses | 13.64M | 61.00K | -42.00K | -24.00K | -1.44M | -33.00K | -227.00K |
| Operating Expenses | 128.14M | 128.88M | 97.01M | 62.26M | 44.50M | 25.58M | 19.82M |
| Cost & Expenses | 183.42M | 180.58M | 150.85M | 120.79M | 87.63M | 51.54M | 31.56M |
| Interest Income | 5.90M | 2.40M | 367.00K | 949.00K | 1.62M | 293.00K | 100.00K |
| Interest Expense | 110.00K | 201.00K | 184.00K | 2.00K | 1.13M | 1.89M | 1.30M |
| Depreciation & Amortization | 11.30M | 12.88M | 8.96M | 7.17M | 5.73M | 3.07M | 1.22M |
| EBITDA | -96.81M | -104.64M | -59.01M | -34.05M | -18.21M | -14.92M | -21.07M |
| EBITDA Ratio | -131.74% | -173.83% | -76.06% | -45.09% | -34.10% | -27.65% | -224.36% |
| Operating Income | -109.94M | -115.53M | -65.35M | -42.15M | -22.42M | -13.77M | -22.16M |
| Operating Income Ratio | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Total Other Income/Expenses | 1.72M | 2.26M | 141.00K | 923.00K | -2.66M | -6.11M | -1.43M |
| Income Before Tax | -108.21M | -113.28M | -65.21M | -41.22M | -25.08M | -19.88M | -23.59M |
| Income Before Tax Ratio | -147.27% | -174.14% | -76.28% | -52.41% | -38.45% | -52.63% | -251.18% |
| Income Tax Expense | 83.00K | 40.00K | 14.00K | 57.00K | 9.00K | 7.00K | 5.00K |
| Net Income | -108.30M | -113.32M | -65.23M | -41.28M | -25.08M | -19.89M | -23.60M |
| Net Income Ratio | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| EPS Diluted | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| Weighted Avg Shares Out | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
| Weighted Avg Shares Out (Dil) | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
Personalis: Market-Leading Immuno-Oncology Platform Drives Consistent Long-Term Growth
Personalis, Inc. to Present at Biomarkers Week Online 2021
Personalis, Inc. (PSNL) CEO John West on Q1 2021 Results - Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis to Report First Quarter 2021 Financial Results on May 5, 2021
Personalis (PSNL) Stock Jumps 7.9%: Will It Continue to Soar?
PSNL Stock Price Increased 10.14%: Why It Happened
Personalis Announces Changes to its Board of Directors
Personalis, Inc. (PSNL) CEO John West on Q4 2020 Results - Earnings Call Transcript
CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021
Source: https://incomestatements.info
Category: Stock Reports